REG - Eco Animal Health Gp - Result of General Meeting

ECO Animal HealthAnnouncement

21/08/2025 12:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250821:nRSU3038Wa&default-theme=true

RNS Number : 3038W  Eco Animal Health Group PLC  21 August 2025

21 August 2025

ECO Animal Health Group plc

("ECO" or the "Company")

 

Result of General Meeting

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that at a General Meeting held earlier
today, the single special resolution proposed was duly passed.

As a result, trustees of the ECO Animal Health Group Employee Benefit Trust
will shortly commence limited on-market purchases of the Company's ordinary
shares of 5 pence each.

Voting results from the General Meeting will be made available on the
Company's website at https://ecoanimalhealth.com/investors/
(https://ecoanimalhealth.com/investors/) .

-Ends-

 

Contacts

                                                                020 8447 8899

 ECO Animal Health Group plc

 David Hallas (Chief Executive Officer)

 Christopher Wilks (Chief Financial Officer)

 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott

 Jessica Hodgson

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Philip Davies

 Sam Butcher

 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Lydia Zychowska

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

 

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

 

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

 

Our lead product, Aivlosin(®) is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

 

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMFFLFLEVLLBBV